Galderma Group Ltd

Latest Results (11.06.2024):

Record Net Sales

For the first quarter of 2024, Galderma Group Ltd achieved record net sales of 1.071 billion USD, marking the first time the company has surpassed the 1 billion USD threshold in the first three months of a year. This represents a 12.4% year-on-year growth on a constant currency basis, primarily driven by increased volume across all product categories and geographies.

Injectable Aesthetics Growth

Galderma Group Ltd's Injectable Aesthetics segment reported net sales of 511 million USD for the first quarter of 2024, reflecting a 19.3% year-on-year growth on a constant currency basis. This growth was mainly driven by volume, with both sub-categories, Neuromodulators and Fillers and Biostimulators, experiencing double-digit growth.

Dermatological Skincare Performance

The Dermatological Skincare division of Galderma Group Ltd posted net sales of 351 million USD in the first quarter of 2024, achieving an 8.4% year-on-year growth on a constant currency basis. The growth was primarily driven by volume and a favorable product mix, with notable double-digit growth in Cetaphil in International markets and Alastin.

Therapeutic Dermatology Sales

Galderma Group Ltd's Therapeutic Dermatology segment recorded net sales of 209 million USD for the first quarter of 2024, with a year-on-year growth of 4.1% on a constant currency basis. The growth was largely driven by volume in International markets, despite some anticipated lower volumes in the U.S. due to phasing impacts and ongoing genericization.

2024 Financial Outlook

With a strong start to the year, Galderma Group Ltd confirms its full-year guidance for 2024, projecting 7-10% net sales year-on-year growth at constant currency and a Core EBITDA margin in line with 2023. The company's performance in the first quarter demonstrates robust execution of its integrated dermatology strategy and positions it well for sustained growth throughout the year.